Text Size

Incidence of Ocular Antibodies in Patients With Sturge - Weber Syndrome (SWS)

This study has been completed.
Sponsor:
Collaborator:
Mainz University
Information provided by (Responsible Party):
Montana Compton, University of California, Irvine
ClinicalTrials.gov Identifier:
NCT00610402
First received: January 25, 2008
Last updated: October 28, 2011
Last verified: October 2011
History of Changes
  Purpose

Sturge-Weber Syndrome (SWS) is a neurological disorder characterized at birth by seizures and a large port-wine stain birthmark on the forehead and upper eyelid of one side of the face. SWS is also accompanied by an increased pressure within the eye (glaucoma) which can develop very early in life.

Glaucoma represents a group of ocular disorders that are characterized by the loss of retinal ganglion cells and their axons, damage to the optic nerve, and gradual loss of visual field. Recently, several studies provided evidence that there is a potential role of the immune system in the pathogenesis of glaucoma.

These findings suggest that there might be changes in systemic humoral immunity possibly underlying the optic neuropathy in at least some glaucoma patients.


Condition
Sturge - Weber Syndrome (SWS)

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Incidence of Ocular Antibodies in Patients With Sturge - Weber Syndrome (SWS)

Resource links provided by NLM:

MedlinePlus related topics: Glaucoma
U.S. FDA Resources

Further study details as provided by University of California, Irvine:

Biospecimen Retention:   Samples Without DNA

blood sample tear drop sample


Enrollment: 57
Study Start Date: July 2007
Study Completion Date: June 2008
Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)
Detailed Description:

The ocular antibody profile in patients with SWS is unknown.The researchers want to study on blood and tear drop samples from patients with SWS to determine the incidence of ocular antibodies in patients with this syndrome.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

community sample

Criteria

Inclusion Criteria:

  • Male and female volunteers with SWS of all ages

Exclusion Criteria:

  • Volunteers without SWS
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00610402

Locations
United States, California
Beckman Laser Institute Medical clinic
Irvine, California, United States, 92612
Sponsors and Collaborators
Montana Compton
Mainz University
Investigators
Principal Investigator: John S Nelson, M.D,PhD Beckman Laser Institute University of California Irvine
  More Information

No publications provided

Responsible Party: Montana Compton, Administrative Nurse Research Coordinator Beckman Laser Institute, University of California, Irvine
ClinicalTrials.gov Identifier: NCT00610402     History of Changes
Other Study ID Numbers: NIH-LAMMP P41-RR01192
Study First Received: January 25, 2008
Last Updated: October 28, 2011
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Brain Stem Infarctions
Stroke
Klippel-Trenaunay-Weber Syndrome
Sturge-Weber Syndrome
Neurocutaneous Syndromes
Angiomatosis
Vascular Diseases
Cardiovascular Diseases
Hemangioma
Neoplasms, Vascular Tissue
Neoplasms by Histologic Type
Neoplasms
Nervous System Diseases
Ectodermal Dysplasia
Abnormalities, Multiple
 Congenital Abnormalities
Skin Abnormalities
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases
Brain Infarction
Brain Ischemia
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Antibodies
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on June 18, 2013